A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose

Pharmacogenetics and Genomics - Tập 16 Số 10 - Trang 721-726 - 2006
Sarah K. Tate1, Rinki Singh2,3, Chin‐Chuan Hung4,5, Meei‐Fang Lou6, Chantal Depondt7, Gianpiero L. Cavalleri8, Sanjay M. Sisodiya2,3, David B. Goldstein9, Horng‐Huei Liou4,5,10
1Dept of Biology, University College London, London, UK
2Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, Queen Square, London, UK
3National Society for Epilepsy, Chalfont-St-Peter, Bucks, UK
4Neurology, National Taiwan University Hospital and college of Medicine, National Taiwan University, Taipei, Taiwan
5Pharmacology,
6Graduate Institute of Epidemiology, College of Public Health
7Service de Neurologie, Hôpital Erasme, Université Libre de Bruxelles, Brussels Belgium
8Department of Biology, University College London, Darwin Building, Gower Street, London, UK
9Institute for Genome Sciences and Policy, Center for Population Genomics and Pharmacogenetics, Duke University, Durham, North Carolina, USA
10requests for reprints to Dr Horng-Huei Liou, MD, PhD, Departments of Pharmacology and Neurology, National Taiwan University Hospital and College of Medicine, National Taiwan University, 1 Jen-Ai Road, Section 1, Taipei 100, Taiwan.

Tóm tắt

Từ khóa


Tài liệu tham khảo

Tate, 2005, Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin, Proc Natl Acad Sci USA, 102, 5507, 10.1073/pnas.0407346102

Kupfer, 1984, Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man, Eur J Clin Pharmacol, 26, 753, 10.1007/BF00541938

Aynacioglu, 1999, Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin, Br J Clin Pharmacol, 48, 409, 10.1046/j.1365-2125.1999.00012.x

Odani, 1997, Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy, Clin Pharmacol Ther, 62, 287, 10.1016/S0009-9236(97)90031-X

Mamiya, 1998, The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics, Epilepsia, 39, 1317, 10.1111/j.1528-1157.1998.tb01330.x

Hung, 2004, Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms, Ther Drug Monit, 26, 534, 10.1097/00007691-200410000-00012

van der, 2001, The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement, Pharmacogenetics, 11, 287, 10.1097/00008571-200106000-00002

Valodia, 1999, Factors influencing the population pharmacokinetic parameters of phenytoin in adult epileptic patients in South Africa, Ther Drug Monit, 21, 57, 10.1097/00007691-199902000-00009

Battino, 2004, Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data, Epilepsy Res, 59, 155, 10.1016/j.eplepsyres.2004.04.006

Patsalos, 2003, Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs, Lancet Neurol, 2, 473, 10.1016/S1474-4422(03)00483-6

Xie, 2001, Molecular basis of ethnic differences in drug disposition and response, Annu Rev Pharmacol Toxicol, 41, 815, 10.1146/annurev.pharmtox.41.1.815

Thông tin
Thông tin xuất bản

Pharmacogenetics and Genomics

Tập 16 Số 10

721-726

Thông tin tác giả